Angiotensinogen [11002-13-4]

Athens Research

Angiotensinogen [11002-13-4]

9

ELISA Standard & Calibrator, Hypertension research, In Vitro Diagnostic

Research Use Only

≥95% by SDS-PAGE

Angiotensinogen

Angiotensinogen (AGT), a glycoprotein circulating at 2.8–7.1 mg/100 mL in plasma, serves as the precursor for all angiotensin peptides in the renin-angiotensin system (RAS), a critical regulator of blood pressure, fluid balance, and electrolyte homeostasis. Primarily synthesized by the liver, AGT is also produced in the brain, kidneys, adipose tissue, and arterial walls. During pregnancy, total AGT levels surge fourfold, while AGT increases 20-fold, becoming predominant in amniotic fluid (80%). AGT’s structural dynamics involve redox-sensitive disulfide bonds (Cys18-Cys138) and glycosylation, which modulate renin’s access to its cleavage site. As a non-inhibitory SERPIN, AGT lacks protease-inhibitory activity but undergoes conformational changes upon renin binding, releasing angiotensin I (AngI). Subsequent processing yields vasoactive peptides (AngII, Ang1-7, etc.), influencing vascular tone, inflammation, and fibrosis. Plasma AGT levels are upregulated by corticosteroids, estrogen, thyroid hormones, and AngII. Clinically, AGT polymorphisms (e.g., M235T) correlate with hypertension, preeclampsia, and cardiovascular diseases. Elevated AGT in pregnancy associates with gestational hypertension and preeclampsia. Emerging therapies target AGT via antisense oligonucleotides or siRNA to attenuate RAS activity, offering novel approaches for hypertension and heart failure. AGT’s form also serves as a biomarker for pregnancy-related hypertensive disorders.

more then 1 year

Source human plasma non-reactive for HBsAG, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA approved tests.

-20C

41116100